38 results
8-K
EX-99.1
PRME
Prime Medicine Inc
10 May 24
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
8:05am
presented new preclinical data showcasing the safety and broad potential of our Prime Editing technology across our pipeline programs and highlighting our … trial is a multinational, first-in-human trial designed to assess the safety, biological activity and preliminary efficacy of PM359 in adult
8-K
EX-1.1
PRME
Prime Medicine Inc
16 Feb 24
Entry into a Material Definitive Agreement
6:23am
of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively
424B5
PRME
Prime Medicine Inc
16 Feb 24
Prospectus supplement for primary offering
6:17am
, across multiple editing programs, suggest a potentially best-in-class safety profile.
Recent Enhancements
We have designed proprietary high throughput … for autologous cell therapy, cell quality issues, and safety risks associated with semi-random integration and double strand breaks at multiple genomic loci
424B5
j36oynud6kai4q
14 Feb 24
Prospectus supplement for primary offering
5:27pm
8-K
EX-99.1
xtf00rx2nyxlv dga4sv
8 Jan 24
Regulation FD Disclosure
8:01am
S-3
EX-1.2
vo9k9i4gljc
3 Nov 23
Shelf registration
5:23pm
8-K
EX-99.1
7het4m
3 Nov 23
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
4:06pm
8-K
EX-99.2
jnth70omwz 0hmu35jc
7 Aug 23
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
4:04pm
8-K
EX-99.1
6v8dgrv9 n38uje87iu
17 May 23
Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting
7:09am
8-K
EX-99.1
w1x13
11 May 23
Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates
8:05am
10-Q
xq4bsooylz1k
14 Nov 22
Quarterly report
4:46pm
424B4
7rv7z
21 Oct 22
Prospectus supplement with pricing info
4:47pm